3

Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)

ItemPFSOS
P HR (95%CI)P HR (95%CI)
Post-treatment ECOG score0.0022.073 (1.315, 3.269)
Post-treatment granulocytes/lymphocytes ratio< 0.0012.183 (1.523, 3.130)< 0.0012.423 (1.642, 3.576)
Pre-randomization maximal target lesion length0.0031.690 (1.190, 2.400)
Hypertension0.0400.688 (0.481, 0.983)
Hand-foot syndrome0.0020.582 (0.415, 0.815)
Hyperglycemia0.0070.632 (0.453, 0.884)
Hypertriglyceridemia0.0020.545 (0.569, 1.535)0.0020.520 (0.347, 0.778)
Elevated thyroid stimulating hormone0.0030.573 (0.399, 0.822)
Elevated alkaline phosphatase0.0441.425 (1.010, 2.011)